ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
87.49
-0.27 (-0.31%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close87.76
Open88.29
Bid87.26 x 900
Ask87.35 x 800
Day's Range87.45 - 88.32
52 Week Range62.87 - 88.33
Volume5,824,075
Avg. Volume5,207,571
Market Cap154.348B
Beta (3Y Monthly)0.87
PE Ratio (TTM)53.81
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (1.46%)
Ex-Dividend Date2019-07-12
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire5 days ago

    Abbott Reports Second-Quarter 2019 Results

    - Accelerated and sustainable growth driven by strong performance across portfolio - Raising full-year guidance for organic sales growth to 7 to 8 percent - Double-digit EPS growth exceeded expectations; ...

  • ACCESSWIRE5 days ago

    Abbott Laboratories to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Abbott Laboratories (NYSE: ABT ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 17, 2019 at 9:00 AM Eastern ...

  • PR Newswire7 days ago

    Abbott Receives U.S. Approval of Next-Generation MitraClip®, Bringing New Enhancements to Abbott's Leading MitraClip Platform

    ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ -- Abbott (ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of physicians across the U.S. by delivering an expanded range of clip sizes, an alternative leaflet grasping feature and facilitation of procedure assessment in real time to offer doctors further options when treating mitral valve disease.

  • PR Newswire11 days ago

    Abbott Announces FDA Approval of the Alinity™ s System, the Latest Technology for Screening and Protecting the U.S. Blood and Plasma Supply

    ABBOTT PARK, Ill., July 11, 2019 /PRNewswire/ -- Abbott (ABT) announced today U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity™ s System.  This new solution will bring the latest screening technology to U.S. blood and plasma centers. Alinity s is designed to screen blood and plasma more efficiently within a smaller space versus commercially available competitive systems. In a testing specialty that can require extensive hands-on time, the additional automation and flexibility of Alinity s will help blood and plasma centers improve productivity and maintain the highest levels of accuracy. "Alinity s is a significant leap forward when it comes to speed, automation and efficiency for blood and plasma screening," said Louis Morrone, vice president, Transfusion Medicine, Abbott.

  • PR Newswire28 days ago

    Nutrition Is the Missing Ingredient in Home Health Today, New Study Shows

    ABBOTT PARK, Ill., June 24, 2019 /PRNewswire/ -- New research from Advocate Health Care and Abbott (ABT) found that prioritizing nutrition care* for home health patients at risk for malnutrition had a dramatic impact on helping keep them out of the hospital - resulting in millions of dollars in healthcare cost savings. Nearly 5 million Americans annually rely on home healthcare to recover from an illness, injury or hospitalization.1,† While healthcare providers are constantly striving to improve patients' health and minimize hospitalizations, nutrition is often not top of mind, yet it plays a critical role in helping adults bounce back and resume their normal routine.

  • PR Newswirelast month

    Abbott Hosts Conference Call for Second-Quarter Earnings

    ABBOTT PARK, Ill., June 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019 , before the market opens.  The announcement will ...

  • PR Newswirelast month

    CARE, Abbott and the Abbott Fund Launch Partnership to Address Noncommunicable Diseases (NCDs) in Humanitarian Settings

    ATLANTA and ABBOTT PARK, Ill., June 17, 2019 /PRNewswire/ -- The global humanitarian organization CARE, the healthcare company Abbott (ABT) and its foundation the Abbott Fund today announced a three-year, $1 million program to screen, diagnose, prevent and manage noncommunicable diseases (NCDs) for people who remain displaced two years after armed conflict in Marawi City, Philippines. The partnership is among the first of its kind to address NCDs in areas affected by disasters, conflict and other humanitarian challenges.

  • PR Newswirelast month

    Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes

    - Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation - Assay is the first and only rapid point-of-care ...

  • PR Newswirelast month

    Abbott Declares 382ⁿᵈ Consecutive Quarterly Dividend

    ABBOTT PARK, Ill., June 14, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. This marks the 382 nd consecutive quarterly ...

  • PR Newswirelast month

    New Survey Shows Millennials Can Help Avoid Blood Shortages

    ABBOTT PARK, Ill., June 13, 2019 /PRNewswire/ -- A new survey from Abbott (ABT) finds that millennials may be the key to a growing public health problem: a shortage in donated blood. Historically, 45% of blood donations in the U.S. are from people 50 and older.1 A large portion of these regular donors are baby boomers who are starting to reach an age when they develop health problems that make them ineligible to give blood. "Millennials are known for wanting to positively impact global issues, and we are hoping to see that passion applied to donating blood," said Alexander Carterson, M.D., Ph.D., global medical director, Transfusion Medicine, Abbott.

  • PR Newswirelast month

    New Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels in People Living with Type 2 Diabetes

    SAN FRANCISCO, June 8, 2019 /PRNewswire/ -- Today Abbott (ABT) announced new data showing use of its FreeStyle Libre system, the company's revolutionary continuous glucose monitoring (CGM) technology, significantly reduced hemoglobin A1c (HbA1c) levels for people living with Type 2 diabetes on intensive insulin therapy.2 The results were analyzed from retrospective, real-world data in three countries across Europe and presented as a late-breaker (Abstract 99-LB) at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco. The goal of the combined analysis of three individual studies was to determine the impact of using the FreeStyle Libre system on glycemic control in people on intensive insulin therapy living with Type 2 diabetes, the most common form of diabetes where the body is unable to make enough insulin to keep blood glucose levels normal.

  • PR Newswire2 months ago

    TRILUMINATE Study Shows Treatment with Abbott's First-of-its-Kind Minimally Invasive Device Reduces Tricuspid Heart Valve Leaks

    - Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR - Data suggest the first-of-its-kind device reduces difficult-to-treat tricuspid regurgitation ...

  • PR Newswire2 months ago

    New ZonePerfect® Keto is 100% #TrueKeto with the Proven Blend of Macros for Effective Results

    ABBOTT PARK, Ill., May 16, 2019 /PRNewswire/ -- You don't need to follow #TransformationTuesday on Instagram or read the latest pop culture magazine to know that nearly half of Americans are trying to lose weight.1 The ketogenic or "keto" diet – a high fat, moderate protein and very low carbohydrate eating pattern – is proven to be an effective weight management plan when followed correctly,2 yet not all keto products on the market have the right ratio of macronutrients ("macros") to yield the best results. To address this need, Abbott (ABT) is launching new ZonePerfect® Keto made with 75% fat, 20% protein and 5% carbs.

  • PR Newswire2 months ago

    Nearly 9 out of 10 College Students with Student Debt Say It's Important to Find a Company That Offers Loan Relief

    ABBOTT PARK, Ill., May 15, 2019 /PRNewswire/ -- Student loan debt – affecting 1 in 4 Americans and topping $1.5 trillion – is one of the most pressing concerns of students graduating college this spring. Nearly 70% of graduates today have taken out a loan – and a recent survey of college students shows that 9 out of 10 of them are on the hunt for a company with a student loan perk.

  • PR Newswire2 months ago

    Abbott Partners With NIH On BRAIN Initiative to Advance Research for Neurological Disorders

    ABBOTT PARK, Ill., May 14, 2019 /PRNewswire/ -- Abbott (ABT) today announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neuroscience research.  As part of the agreement, Abbott will provide the company's neuromodulation technologies—including directional deep brain stimulation (DBS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) therapy—for research related to these NIH initiatives to explore their application for chronic pain and progressive movement disorders, like Parkinson's disease.

  • PR Newswire2 months ago

    Abbott to Present at UBS Global Healthcare Conference

    ABBOTT PARK, Ill., May 7, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Brian Yoor , executive vice president of finance and chief ...

  • Abbott Launches Next-generation Detection Technology in the U.S. and Europe, Offering a Smarter Approach to 24/7 Heart Monitoring for People with Irregular Heartbeats
    PR Newswire3 months ago

    Abbott Launches Next-generation Detection Technology in the U.S. and Europe, Offering a Smarter Approach to 24/7 Heart Monitoring for People with Irregular Heartbeats

    ABBOTT PARK, Ill., May 6, 2019 /PRNewswire/ -- Abbott today announced the launch of a new, smarter heart monitor for better arrhythmia detection—positive news for people at risk for irregular heartbeats. Now with CE Mark in Europe and U.S. Food and Drug Administration (FDA) clearance, the next-generation Confirm Rx™ insertable cardiac monitor (ICM), a paperclip-sized implantable device, combines smartphone connectivity and continuous, remote monitoring to track unpredictable heart rhythm problems for fast and accurate diagnosis.

  • PR Newswire3 months ago

    Abbott Receives WHO Prequalification Approval for Breakthrough HIV Point-of-Care Test

    - WHO Prequalification approval allows Abbott to bring critical technology to more resource-limited settings - Confirms that the m-PIMA™ HIV-1/2 VL meets global standards of quality, safety and efficacy ...

  • PR Newswire3 months ago

    Abbott, the U.S. Department of Defense and TRACK-TBI Partner to Study Point-of-Care Blood Test for Concussions

    ABBOTT PARK, Ill., April 30, 2019 /PRNewswire/ -- Abbott (ABT) today announced the next phase of partnership with the U.S. Department of Defense (DoD) and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury (TBI) efforts of its kind. "Traumatic brain injury is a significant health issue affecting both active Service Members and Veterans, and we are committed to developing solutions for those impacted by brain injury," said Krista Caudle, Ph.D., project manager, Neurotrauma and Psychological Health Project Management Office, U.S. Army Medical Materiel Development Activity (USAMMDA).

  • PR Newswire3 months ago

    New Study Finds Abbott Blood Test Can Help Predict Future Cardiac Events in Adults with No Known Heart Disease

    ABBOTT PARK, Ill., April 29, 2019 /PRNewswire/ -- Abbott (ABT) announced today that a new study published in Circulation found its High Sensitive Troponin-I blood test could predict the chance of developing a cardiac event years before it occurs in people with no symptoms when added to current heart disease assessments.1 Using data from the Atherosclerosis Risk in Communities (ARIC) study, researchers suggest doctors could add the test to routine physical assessments in healthy middle-aged and older adults to better predict their chances of developing heart disease.

  • PR Newswire3 months ago

    Abbott Reports First-Quarter 2019 Results

    - Sales and EPS growth exceed guidance; projects strong full-year outlook - Long-term growth drivers - including FreeStyle Libre, MitraClip and Alinity - achieved strong double-digit growth - Reported ...

  • PR Newswire3 months ago

    Abbott and the Abbott Fund Support Relief Efforts for Cyclone Idai

    ABBOTT PARK, Ill., April 11, 2019 /PRNewswire/ -- Abbott (ABT) and its foundation, the Abbott Fund, are providing more than $500,000 in grants and healthcare products to support relief efforts for Cyclone Idai in Southeast Africa, including Mozambique, Malawi and Zimbabwe. According to the United Nations, significant aid is needed to help meet immediate needs across the region, following the devastating impact of Cyclone Idai and continued heavy rains and flooding. This includes focused efforts in Mozambique to address cholera, malaria and other diseases, as well as to meet immediate needs for food, water, shelter and medical care across the region.

  • PR Newswire4 months ago

    Abbott Hosts Conference Call for First-Quarter Earnings

    ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019 , before the market opens.  The announcement will ...

  • PR Newswire4 months ago

    Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients

    This new technology will help keep up with the growing demand for infectious disease testing. Alinity m will provide unprecedented flexibility in molecular diagnostic testing, allowing more tests to be done in shorter timeframes, while reducing the space and number of instruments needed to conduct large amounts of tests.

  • PR Newswire4 months ago

    New Data for Abbott's HeartMate 3™ Highlights Unparalleled Performance of Industry's Leading Heart Pump

    NEW ORLEANS, March 17, 2019 /PRNewswire/ -- Abbott (ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world's largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing data across the complete 1,028 patient cohort, MOMENTUM 3 met its primary endpoint of event free survival while showcasing improved rates of overall survival, quality of life and a reduction in adverse events with the HeartMate 3™ left ventricular assist device (LVAD).